453 - The Risk of Diarrhea and Colitis in Patients with Lung Cancer Undergoing Immune-Checkpoint Inhibitor Therapy
Kirles Bishay(University of Ottawa), Jeffrey D. McCurdy(University of Ottawa), Simon Parlow(University of Ottawa), Parul Tandon(University of Ottawa), Samuel Bourassa‐Blanchette(University of Ottawa), Scott A. Laurie(Ottawa Hospital)
Cited by 2
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
|Journal of Clinical Oncology|2006|504
Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock
|Journal of the American College of Cardiology|2019|398
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
|The Lancet Oncology|2010|394
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
|Journal of Clinical Oncology|2017|366